MDLinx, Inc. Acquired by So-net M3, a Sony Communication Network Group Company

May 9, 2006

WASHINGTON, D.C. – May, 19, 2006–MDLinx, ( a leading online provider of global, real-time health information resources for physicians and consumers, announced today it has entered into a definitive merger agreement with So-net M3, a Sony Communication Network Group company.

MDLinx is an online healthcare media company that owns and operates a network of 32 medical portals, 36 consumer health portals, and 740 different email newsletters that provide highly focused, clinical updates to over 200,000 physicians, healthcare professionals, and a growing number of patients and consumers. MDLinx’s revenues derive from online advertising and sponsorship programs, market research, and content licensing. The company works with most of the world’s 20 largest pharmaceutical companies.

So-net M3 is Japan’s leading provider of online pharmaceutical marketing services with a public equity market capitalization of approximately $1.1 billion. So-net M3 has used its proprietary online pharmaceutical marketing software, Visits, to achieve a leading position in the online pharmaceutical marketing market in Japan, the second largest pharmaceutical market after the United States. The company, which is 60% owned by Sony Communication Network (part of the Sony Group), is traded on the Tokyo Stock Exchange.

“By becoming part of the Sony family, MDLinx will be able to provide our users and our pharmaceutical customers with larger and deeper offerings,” said MDLinx C.E.O. Dave Rothenberg. “Our market research business is strengthened by access to Asian physicians, our sponsorship business can deliver more extensive international reach, and we can provide clients with more interactive online marketing services.”

Itaru Tanimura, President and C.E.O. of So-net M3 explained, “MDLinx’s sustained and growing profitability, its high usage among US physicians, and its award winning content made it a very attractive partner for us as we look to expand to the US market.”

Closing is expected before the end of June 2006. England & Company served as the exclusive financial advisor to MDLinx in this transaction.

About MDLinx

MDLinx ( is an award-winning, practical tool that busy physicians, healthcare professionals, and a growing number of educated consumers use to stay up to date with the latest research in the medical field. The company aggregates medical articles and research from more than 1,200 peer-reviewed journals and leading news media on a daily basis. Physician editors sort this content into 32 medical specialty sites, 36 patient sites, and more than 743 subspecialty sections, all available online. Users can choose to view this information online or subscribe to any of the 743 daily newsletters.

For the pharmaceutical and healthcare industries, MDLinx provides a unique way to communicate directly with physicians and healthcare consumers. MDLinx offers advertising, content licensing, and market research solutions that help companies broadcast product messages and build brand awareness among their target audiences. MDLinx works with nine of the world’s ten largest pharmaceutical companies to provide unparalleled online access to sought-after target groups.

For more information, please contact:

Sandra Jerez
MDLinx, Inc.
1232 22nd Street, NW, Suite 200
Washington, D.C. 20037
Phone: (202) 293- 1682
Fax: (202) 293-1690